祁玉娟, 才保加, 杨应忠, 陈海军, 格日力. 高海拔地区 ERCC1 和 TSER 基因多态性与奥沙利铂联合希罗达治疗进展期胃癌的相关性研究[J]. 中国肿瘤临床, 2012, 39(18): 1367-1370，1374. DOI: 10.3969/j.issn.1000-8179.2012.18.009
引用本文: 祁玉娟, 才保加, 杨应忠, 陈海军, 格日力. 高海拔地区 ERCC1 和 TSER 基因多态性与奥沙利铂联合希罗达治疗进展期胃癌的相关性研究[J]. 中国肿瘤临床, 2012, 39(18): 1367-1370，1374. DOI: 10.3969/j.issn.1000-8179.2012.18.009
shu
Yujuan QI, Baojia CAI, Yingzhong YANG, Haijun CHEN, Rili GE. Correlation between Genetic Polymorphisms of Excision Repair Cross-Complementation Group 1 and Thymidylate Synthase Enhancer Region and Chemotherapeutic Effects of Oxaliplatin/Xeloda on Advanced Gastric Cancer in High-Altitude Localities[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(18): 1367-1370，1374. DOI: 10.3969/j.issn.1000-8179.2012.18.009
Citation: Yujuan QI, Baojia CAI, Yingzhong YANG, Haijun CHEN, Rili GE. Correlation between Genetic Polymorphisms of Excision Repair Cross-Complementation Group 1 and Thymidylate Synthase Enhancer Region and Chemotherapeutic Effects of Oxaliplatin/Xeloda on Advanced Gastric Cancer in High-Altitude Localities[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(18): 1367-1370，1374. DOI: 10.3969/j.issn.1000-8179.2012.18.009
shu

高海拔地区 ERCC1 和 TSER 基因多态性与奥沙利铂联合希罗达治疗进展期胃癌的相关性研究

Correlation between Genetic Polymorphisms of Excision Repair Cross-Complementation Group 1 and Thymidylate Synthase Enhancer Region and Chemotherapeutic Effects of Oxaliplatin/Xeloda on Advanced Gastric Cancer in High-Altitude Localities

    摘要
  • 摘要:
      目的  探讨高海拔地区切除修复交叉互补基因1(excision repair cross-complementation group 1, ERCC1)、胸苷酸合成酶增强子(thymidylate synthase enhancer region, TSER)的基因多态性, 及与奥沙利铂联合希罗达治疗进展期胃癌的相关性研究。
      方法  122例进展期胃癌患者入组并行奥沙利铂联合希罗达化疗, 110例患者按要求完成治疗并随访PCR-RFLP检测基因位点的多态性, 分析基因多态性与化疗客观反应率(response rate, RR)和无进展生存(progression-free survival, PFS)的关系。
      结果  ERCC1118C/T位点的多态性与奥沙利铂联合希罗达治疗后的RR、PFS期无相关性(P=0.221, P=0.186)TSER基因为2R/2R、2R/3R型患者的RR和PFS期优于3R/3R型(P=0.037, P=0.033)。
      结论  高海拔地区, 奥沙利铂联合希罗达治疗进展期胃癌中ERCC1基因多态性与RR、PFS期无相关性, TSER基因多态性与RR。

     

    Abstract:
      Objective  To investigate the value of genetic polymorphisms of excision repair cross-complementation group 1 (ERCC1) and thymidylate synthase enhancer region (TSER) in predicting the prognosis of advanced gastric cancer patients treated with oxaliplatin/ Xeloda chemotherapy.
      Methods  Atotal of 122 patients with advanced gastric cancer were enrolled in this study, of which 110 were eligible for analysis. All patients repeated received oxaliplatin / Xeloda chemotherapy every two cycles. PCR - RFLP method was used for analyzing the ERCC1 and TSER polymorphism. Then the relationships among the genetic polymorphisms and response rate (RR), progression free survival (PFS) time were analyzed.
      Results  No significant correlation in PFS and RR was observed between patients with the C / C or C / T genotype in ERCC1 118C / T and those with the T/T genotype (P= 0.221, P= 0.186). Meanwhile, a higher response rate and longer PFS was observed in patients with the 2R2R or 2R3R genotype in TSER compared to those with the 3R3R genotype (P= 0.037, P= 0.033).
      Conclusion  The genetic polymorphism of ERCC1 118C / T is not significantly correlated with PFS and RR in predicting the prognosis ofadvanced gastric cancer patients who underwent oxaliplatin /Xeloda chemotherapy. Conversely, the genetic polymorphism of TSER has a certain correlation with this therapy in high-altitude localities.

     

    • HTML全文
    • 参考文献(12)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回